ArticleCancer discovery2019
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.
Abstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.JCO precision oncology · 2025Pooled it
- RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Cancer cell · 2026Article
- Precision Oncology Through Dialogue: AI-HOPE-RTK-RAS Integrates Clinical and Genomic Insights into RTK-RAS Alterations in Colorectal Cancer.Biomedicines · 2025Article
- Neobractatin and Trametinib Synergistically Induce Apoptosis and Gasdermin E-Dependent Pyroptosis in Pancreatic Cancer Cells.MedComm · 2025Article
- Nickase fidelity drives EvolvR-mediated diversification in mammalian cells.Nature communications · 2025Article
- Orthogonal RNA replication enables directed evolution and Darwinian adaptation in mammalian cells.Nature chemical biology · 2025Article
- Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.Frontiers in oncology · 2025Article
- Article
- The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.Chemical science · 2024Review
- Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024Review
- Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.EMBO molecular medicine · 2024Article
- Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.The oncologist · 2024Article
- Forkhead box D subfamily genes in colorectal cancer: potential biomarkers and therapeutic targets.PeerJ · 2024Article
- optima: an open-source R package for the Tapestri platform for integrative single cell multiomics data analysis.Bioinformatics (Oxford, England) · 2023Article
- Transitioning single-cell genomics into the clinic.Nature reviews. Genetics · 2023Review
- Gain-of-function mutations in the catalytic domain ofScience advances · 2023Article
- Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer.Nature communications · 2023Article
- High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.Molecular cancer therapeutics · 2023Article
- Conquering oncogenic KRAS and its bypass mechanisms.Theranostics · 2022Review
- An overview of kinase downregulators and recent advances in discovery approaches.Signal transduction and targeted therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Yijun GaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ann MariaProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Na NaProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Arnaud da Cruz PaulaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexander N GorelickDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jaclyn F HechtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Julianne CarsonProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert A LefkowitzDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Barry S TaylorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
HuiYong ZhaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Neal RosenProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8307-654X
Zhan YaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. yaegerr@mskcc.org.
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MExploiting the distinct genomics and signaling of colorectal cancers to effectively target ERKR01CA233736 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI YAEGER, RONA · 2019 to 2024
$2.5MUnderstanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA233736NCI NIH HHS R35 CA210085NIH HHS U54 OD020355
Abstract
We report the emergence of the novel
Indexed as
Amino Acid SubstitutionDrug Resistance, NeoplasmAdultAllosteric RegulationAnimalsBenzimidazolesBinding SitesCell Line, TumorColonic NeoplasmsFemaleHumansMAP Kinase Kinase 1MiceNIH 3T3 CellsProtein BindingProtein Kinase InhibitorsBenzimidazolesbinimetinibBRAF protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Protein Kinase InhibitorsProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.